论文部分内容阅读
AIM: To investigate the impact of telaprevir-based triple therapy on the serum alpha-fetoprotein(AFP) level of chronic hepatitis C patients.METHODS: A total of 210 patients with chronic hepatitis C genotype 1 of high viral load(baseline serum hepatitis C virus RNA > 5.0 log10 IU/m L) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α(PEGIFNα), and ribavirin(RBV) for 24 wk(n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk(n = 122). The relationship between virological response and the change in the serum AFP level from baseline to 24 wk after the end of treatment was examined. RESULTS: No significant difference in mean baseline AFP level was found between the triple and dual therapy groups(8.8 ng/m L vs 7.8 ng/m L). Triple therapy produced significant declines in the AFP level in sustained virological response(SVR) and non-SVR patients(7.8 ng/m L at baseline to 3.5 ng/m L at 24 wk after the end of treatment, P < 0.001 and 14.3 ng/m L to 9.5 ng/m L, P = 0.004, respectively). In contrast, dual therapy resulted in a significant decline in AFP level only in SVR patients(4.7 ng/m L to 2.8 ng/m L, P< 0.001), but not in non-SVR patients(10.2 ng/m L to 10.1 ng/m L). Among patients with a high-baseline AFP level(≥ 10 ng/m L), the decline in the AFP level was significantly higher in the triple therapy than in the dual therapy group(15.9 ng/m L vs 1.6 ng/m L, P = 0.037). CONCLUSION: Regardless of virological response, telaprevir-based triple therapy reduced the serum AFP level.
AIM: To investigate the impact of telaprevir-based triple therapy on the serum alpha-fetoprotein (AFP) level of chronic hepatitis C patients. METHODS: A total of 210 patients with chronic hepatitis C genotype 1 of high viral load virus RNA> 5.0 log10 IU / mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-alpha (PEGIFN alpha), and ribavirin (RBV) for 24 wk therapy with PEG-IFNα and RBV for 48 wk (n = 122). The relationship between virological response and the change in the serum AFP level from baseline to 24 wk after the end of treatment was examined. RESULTS: No significant difference in mean baseline AFP level was found between the triple and dual therapy groups (8.8 ng / m L vs 7.8 ng / m L). Triple therapy produced significant declines in the AFP level in sustained virological response (SVR) and non-SVR patients (7.8 ng / m L at baseline to 3.5 ng / m L at 24 wk after the end of treatment, P <0.001 and 14.3 ng / m L to 9.5 ng / m L, P = 0.004, respectively). In contrast, dual therapy resulted in a significant decline in AFP level only in SVR patients (4.7 ng / m L to 2.8 ng / m L, P <0.001), but not in non-SVR patients (10.2 ng / m L to 10.1 ng / m L). Among patients with a high-baseline AFP level (≥ 10 ng / m L), the decline in the AFP level was significantly higher in the triple therapy than in the dual therapy group (15.9 ng / m L vs. 1.6 ng / m L, P = 0.037). CONCLUSION: Regardless of virological response, telaprevir-based triple therapy reduced the serum AFP level.